アトリアルフィブリレーションを患っている高齢の東アジアの患者における経口抗凝固薬の臨床結果: 一つのセンターでの遡及的研究
PubMedで要約を見る
まとめ
この要約は機械生成です。経口抗凝固剤 (DOAC) は,年齢に関係なく,心房細動 (AF) の高齢患者にとって安全で有効です. 抗凝固薬の治療決定は,年齢のみでなく,臨床的要因によって決められるべきである.
科学分野
- 心臓病科
- 高齢者医療
- 薬理学について
背景
- 高齢者における心拍動不良は,一般的な心拍動不良であり,危険性があります.
- 高齢者のAFの管理は,出血と血栓塞栓の危険性により困難です.
- 非弁動脈動脈症の東アジアの高齢患者は,特定の結果評価を必要とします.
研究 の 目的
- 経口抗凝固剤を投与された非弁性AFの高齢患者における臨床結果の評価.
- 抗凝固薬を受けた年齢層 (70~79歳および80歳以上) の間のアウトカムを比較する.
- 異なる年齢層におけるワーファリンと対比して直接投与される経口抗凝固剤 (DOAC) の安全性と有効性を評価する.
主な方法
- 70歳以上の502人の患者で実施された単一センターでの遡及研究.
- 直接経口抗凝固剤 (DOAC) またはワルファリンを投与された患者
- 70~79歳と80歳以上
主要な成果
- 80歳以上の患者は数値的に出血率が高かったが,調整後に統計的に有意ではなかった.
- 発血と血栓塞栓の発生率は,年齢層間で比較可能であった.
- DOACsとワルファリンは,年齢グループごとに調整されたとき,同様の安全性および有効性プロファイルを示しました.
結論
- 経口投与の直接抗凝固剤 (DOAC) は,非常に高齢の東アジア系AF患者において安全かつ有効である.
- 臨床的要因に基づく個別化された治療決定は,年齢のみで推奨されます.
- 適切な管理は,抗凝固薬で高齢のAF患者に好ましい結果を保証します.
関連する概念動画
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

